The week in pharma: action, reaction and insight – week to May 23

By Barbara Obstoj-Cardwell. Editor

Last week saw Novavax receive full approval from the US Food and Drug Administration (FDA) for its COVID-19 vaccine, but with post-market requirements. Swiss gene-editing company CRISPR Therapeutics linked up with Sirius Therapeutics to develop siRNA therapeutics, notably the latter’s SRSD107 in cardiovascular indications. The FDA last week announced a new executive order aiming to provide a pathway for prescription drugs from Canada, Also of note, Gilead Sciences released positive results for its Trodelvy ASCENT-03 study in metastatic triple negative breast cancer (mTNBC).

Nuvaxovid FDA approval narrowed, but in line with ACIP